Key Points
- Roivant CEO Eric Venker sold 200,000 shares on Feb. 13 at $26.49 for $5,298,000, leaving him with 1,654,597 shares (a 10.78% reduction in his stake).
- Across recent trades from Dec. 9 to Feb. 13 he sold a total of 875,000 shares for roughly $20.0 million in proceeds.
- Roivant (NASDAQ:ROIV) trades near its 52-week high and has a market cap of about $19.7 billion, with analysts holding a consensus rating of "Moderate Buy" and a $28.69 average price target.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,654,597 shares of the company's stock, valued at $43,830,274.53. The trade was a 10.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Eric Venker also recently made the following trade(s):
- On Monday, January 12th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $21.92, for a total value of $4,384,000.00.
- On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.53, for a total value of $1,689,750.00.
- On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.45, for a total value of $4,490,000.00.
- On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.85, for a total transaction of $4,170,000.00.
Roivant Sciences Trading Up 1.4%
Shares of NASDAQ ROIV opened at $27.48 on Thursday. The stock has a market cap of $19.67 billion, a price-to-earnings ratio of -23.49 and a beta of 1.22. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $27.94. The company's 50-day moving average price is $23.09 and its 200 day moving average price is $18.69.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on ROIV shares. Wall Street Zen raised shares of Roivant Sciences from a "strong sell" rating to a "hold" rating in a research note on Sunday, November 16th. Weiss Ratings cut Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a report on Monday, February 9th. Leerink Partners boosted their price target on Roivant Sciences from $29.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, December 15th. Guggenheim upped their price objective on Roivant Sciences from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Finally, The Goldman Sachs Group lifted their price objective on Roivant Sciences from $24.00 to $33.00 and gave the stock a "buy" rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $28.69.
View Our Latest Research Report on ROIV
Institutional Investors Weigh In On Roivant Sciences
A number of hedge funds and other institutional investors have recently made changes to their positions in ROIV. Penn Davis Mcfarland Inc. increased its holdings in Roivant Sciences by 10.1% during the 3rd quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company's stock worth $28,173,000 after purchasing an additional 170,456 shares during the last quarter. Valeo Financial Advisors LLC bought a new position in Roivant Sciences during the second quarter worth $1,145,000. IFG Advisory LLC bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at about $255,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Roivant Sciences in the 2nd quarter worth approximately $3,064,000. Finally, Franklin Resources Inc. acquired a new position in shares of Roivant Sciences during the second quarter valued at $997,000. Hedge funds and other institutional investors own 64.76% of the company's stock.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
